Psychedelics dogged by low-quality evidence

4 minute read


The TGA down-scheduled MDMA for the treatment of PTSD in 2023, but a full clinical practice guideline hasn’t been published yet.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×